Logo

OncoBlast-Personalized Lung Cancer Care: Updates on Efficacy, Toxicity, and Clinical Decision-Making

This CME-accredited OncoBlast activity uses gamified, case-based questions to reinforce key updates in the management of advanced non-small cell lung cancer (NSCLC). Topics include biomarker-driven therapies (EGFR, ALK, MET, BRAF, KRAS, HER2), treatment sequencing, and toxicity management. Learners will apply evidence-based strategies to real-world scenarios and stay current with the latest approvals and guidelines in precision oncology.

Course Accreditations

Course Summary

Events StartsEvents Ends
N/AN/A

Faculty

Mohana Roy   (MD, Stanford Medicine)

Dr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in hematology and oncology. Dr. Roy became an oncologist because of her passion for patient care. She is committed to being a clinician and is focused on improving the patient experience -- from the moment a patient checks in, to how information about their care is conveyed, and how the complex process of getting cancer care can be made a bit more seamless. Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs) and their use to help clinical quality efforts, She is the recipient of both a clinical innovation award through Stanford and an American Society of Clinical Oncology (ASCO) Merit award. She is the Associate Medical Director for Quality at Stanford Cancer Center.

Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Financial Support Ineligible company: Regeneron Inc Topic: Lung Cancer Treatments Attribution: Self Type of financial relationship: Financial Support Ineligible company: BMS Topic: Lung Cancer Treatment Relationship end date: 03/01/2024
top-curriculum

    Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows
  • Oncology Nurses

    Learning Objectives

    Upon successful completion of this educational activity, participants will be able to:

  • Identify appropriate targeted therapies for the management of lung cancer.
  • Recognize and manage key toxicities associated with novel lung cancer therapies.
  • Apply current clinical evidence to guide treatment sequencing decisions in metastatic NSCLC.